Supernus Pharmaceuticals (SUPN) Profit After Tax (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Profit After Tax data on file, last reported at -$211000.0 in Q1 2026.

• On a quarterly basis, Profit After Tax fell 803.33% year-over-year to -$211000.0 in Q1 2026; TTM through Mar 2026 was -$26.9 million, a 136.51% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 152.19% from the prior year.
• Profit After Tax for Q1 2026 stood at -$211000.0, up from -$4.1 million in the prior quarter.
• Over the last five years, Profit After Tax for SUPN reached as high as $38.5 million in Q3 2024 and fell as low as -$45.1 million in Q3 2025.
• Historically, Profit After Tax has averaged $6.4 million across 5 years, with a median of $1.7 million in 2022.
• Across the five-year window, Profit After Tax slumped 1013.44% in 2023 and soared 2496.63% in 2024, its largest moves.
• Year by year, Profit After Tax stood at $25.5 million in 2022, then sank by 95.39% to $1.2 million in 2023, then soared by 1204.51% to $15.3 million in 2024, then sank by 126.78% to -$4.1 million in 2025, then soared by 94.86% to -$211000.0 in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$211000.0 in Q1 2026, -$4.1 million in Q4 2025, and -$45.1 million in Q3 2025.